Stelara ® (ustekinumab) shows positive results in treatment of
systemic lupus erythematosus in phase 2 trial
(Source: Johnson and Johnson)
Source: Johnson and Johnson - November 6, 2017 Category: Pharmaceuticals Source Type: news
J & J's Stelara shows promise against lupus in study
(Reuters) - Johnson& Johnson's blockbuster psoriasis drug Stelara led to a significant reduction in disease activity in patients with systemic lupus compared with a placebo in a midstage clinical trial, according to data released on Saturday. (Source: Reuters: Health)
Source: Reuters: Health - November 4, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Risankizumab outperforms ustekinumab in psoriasis trial
The IL-23 inhibitor risankizumab was superior to ustekinumab in a phase two trial of adult patients with moderate-to-severe chronic plaque psoriasis, researchers report. (Source: Dermatology Times)
Source: Dermatology Times - October 19, 2017 Category: Dermatology Source Type: news
FDA Clears Ustekinumab (Stelara) for Plaque Psoriasis in Teens FDA Clears Ustekinumab (Stelara) for Plaque Psoriasis in Teens
For at least two thirds of patients aged 12 to 17 years who were treated with ustekinumab, cleared skin or minimal psoriasis was achieved at week 12 in a phase 3 study.FDA Approvals (Source: Medscape Med Students Headlines)
Source: Medscape Med Students Headlines - October 16, 2017 Category: Universities & Medical Training Tags: Dermatology News Alert Source Type: news
Janssen announces u.s. fda approval of stelara ® (ustekinumab) for the treatment of adolescents with moderate to severe plaque psoriasis
(Source: Johnson and Johnson)
Source: Johnson and Johnson - October 14, 2017 Category: Pharmaceuticals Source Type: news
J & J psoriasis drug gets expanded U.S. approval for teens
(Reuters) - Johnson& Johnson said on Friday it has received an expanded U.S. approval for its blockbuster psoriasis drug Stelara to treat adolescent patients aged 12 and over with moderate to severe cases of the unsightly skin condition. (Source: Reuters: Health)
Source: Reuters: Health - October 13, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Janssen Announces FDA Approval of Stelara (ustekinumab) for the Treatment of Adolescents with Moderate to Severe Plaque Psoriasis
Horsham, Pa., October 13, 2017 ― Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Stelara (ustekinumab) for the treatment of adolescents (12 years of age or older) with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 13, 2017 Category: Drugs & Pharmacology Source Type: news
NICE approves new type of treatment for Crohn ’s disease
Following NICE recommendations, patients with Crohn ’s disease will have routine NHS access to drug ustekinumab, which offers a new way of treating the condition. (Source: NHS Networks)
Source: NHS Networks - June 22, 2017 Category: UK Health Source Type: news
UK NICE recommends Janssen ’s Ustekinumab treatment for Crohn’s disease
The UK ’s National Institute for Health and Care Excellence (NICE) has recommended Janssen’s Ustekinumab for the treatment of patients with moderate-to-severe Crohn’s disease. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 18, 2017 Category: Pharmaceuticals Source Type: news
Risankizumab More Effective in Psoriasis Than Ustekinumab in Early Trial Risankizumab More Effective in Psoriasis Than Ustekinumab in Early Trial
Selective inhibition of IL-23 with risankizumab may be more effective in treating psoriasis than the less specific ustekinumab; more studies are needed to confirm results and assess.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 19, 2017 Category: Allergy & Immunology Tags: Dermatology News Source Type: news
One Biologic Bests Another in Head-to-Head Psoriasis Trial
(MedPage Today) -- Taltz turns in better results than Stelara on severity indices (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - March 6, 2017 Category: Dermatology Source Type: news
New Results From Second Phase 3 Study Show Significant Efficacy of Guselkumab and Superiority Versus Humira ® in Treatment of Moderate to Severe Plaque Psoriasis
Additional Phase 3 Study Data Show Significant Efficacy of Guselkumab in Patients Experiencing Inadequate Response to STELARA ® in the Treatment of Moderate to Severe Plaque Psoriasis (Source: Johnson and Johnson)
Source: Johnson and Johnson - March 3, 2017 Category: Pharmaceuticals Source Type: news
Janssen Submits Application Seeking FDA Approval Of Stelara ® (Ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 17, 2016 Category: Pharmaceuticals Source Type: news
Janssen Submits Application Seeking FDA Approval of STELARA(R) (Ustekinumab) for the Treatment of Adolescents with Moderate to Severe Plaque Psoriasis
HORSHAM, Pa., Dec. 16, 2016 -- (Healthcare Sales & Marketing Network) -- Janssen Biotech, Inc. (Janssen) announced today the submission of a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval ... Biopharmaceuticals, Dermatology, FDA Janssen, STELARA, ustekinumab, Psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 16, 2016 Category: Pharmaceuticals Source Type: news
Health Canada approves STELARA(R) for the treatment of adults with moderately to severely active Crohn's disease
STELARA® offers a new approach to treating Crohn's disease in Canada, which has one of the highest rates of this inflammatory bowel disease worldwide1
TORONTO, Dec. 14, 2016 (Healthcare Sales & Marketing Network) - Janssen Inc. announced today that... Biopharmaceuticals, Gastroenterology, Regulatory Janssen Pharmaceutical, STELARA, ustekinumab, Crohn's disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 14, 2016 Category: Pharmaceuticals Source Type: news
